{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:45:27Z","timestamp":1792449927446,"version":"4.5.0"},"reference-count":39,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals","doi-asserted-by":"publisher","award":["GlaxoSmithKline (GSK) Research & Development Limit"],"award-info":[{"award-number":["GlaxoSmithKline (GSK) Research & Development Limit"]}],"id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonadherence to inhaled corticosteroids (ICS) in severe asthma is associated with poor control and may impair response to biologics. The primary objective of the present study was to evaluate ICS nonadherence influence on mepolizumab treatment response in adults with severe eosinophilic asthma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective cohort study, we compared ICS nonadherence rates in mepolizumab responders and nonresponders. Adherence was determined using a prescription possession ratio (PPR) of \u226575% to indicate adherence. Mepolizumab response was assessed using the positive response criteria of a \u226550% reduction in exacerbations and\/or in the maintenance oral corticosteroid dose. Predictors of adherence and mepolizumab response were explored using standard statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 190 participants were included in the analysis (enrolment mean\u00b1\n                      <jats:sc>sd<\/jats:sc>\n                      age 52\u00b113\u2005years, 59 (31%) males). There were 153 (80%) responders to mepolizumab who displayed lower median exacerbations than the nonresponders (1 (interquartile range (IQR) 0, 2)\n                      <jats:italic>versus<\/jats:italic>\n                      4 (IQR 2, 7); p=0.002). ICS nonadherence was detected in 30% and 26% of participants prior to and during mepolizumab treatment respectively. ICS nonadherence was more common in nonresponders 12\/23 (52%) than in mepolizumab responders 29\/130 (22%), p=0.002. Nonadherent patients had higher exhaled nitric oxide fraction (\n                      <jats:italic>F<\/jats:italic>\n                      <jats:sub>ENO<\/jats:sub>\n                      ) (ppb) than the adherent patients (median 57 (IQR 35, 81)\n                      <jats:italic>versus<\/jats:italic>\n                      34 (IQR 21, 61); p=0.009). Pre-mepolizumab nonadherence correlated significantly with on-treatment nonadherence (r=0.75, 95% CI 0.67\u20130.81; p&lt;0.0001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      ICS nonadherence was associated with negative response to mepolizumab treatment and raised\n                      <jats:italic>F<\/jats:italic>\n                      <jats:sub>ENO<\/jats:sub>\n                      levels compared to the adherent group. Our findings support the notion for the need for optimisation of ICS adherence during mepolizumab therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00135-2026","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:50:18Z","timestamp":1784825418000},"page":"00135-2026","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Nonadherence to inhaled corticosteroids is associated with negative mepolizumab response"],"prefix":"10.1183","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2885-3000","authenticated-orcid":false,"given":"Mohammed Ghazi","family":"Almutairi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Marriott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahraa","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Caddick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babita","family":"Rajkumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Renwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8615-8778","authenticated-orcid":false,"given":"Adel H.","family":"Mansur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"2026101903500485000_12.5.00135-2026.1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/imj.13441","article-title":"Management of severe asthma: targeting the airways, comorbidities and risk factors","volume":"47","author":"Gibson","year":"2017","journal-title":"Intern Med J"},{"key":"2026101903500485000_12.5.00135-2026.2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2026101903500485000_12.5.00135-2026.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2026101903500485000_12.5.00135-2026.4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/02770903.2023.2294908","article-title":"The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation","volume":"61","author":"Reilly","year":"2024","journal-title":"J Asthma"},{"key":"2026101903500485000_12.5.00135-2026.5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1080\/02770903.2019.1645169","article-title":"Prevalence and predictors of adherence to controller therapy in adult patients with severe\/difficult-to-treat asthma: a systematic review and meta-analysis","volume":"57","author":"Hassan","year":"2020","journal-title":"J Asthma"},{"key":"2026101903500485000_12.5.00135-2026.6","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00017-2020"},{"key":"2026101903500485000_12.5.00135-2026.7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/MCP.0000000000000334","article-title":"Improving adherence to asthma medications: current knowledge and future perspectives","volume":"23","author":"Blake","year":"2017","journal-title":"Curr Opin Pulm Med"},{"key":"2026101903500485000_12.5.00135-2026.8","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00075614"},{"key":"2026101903500485000_12.5.00135-2026.9","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1513\/AnnalsATS.201608-602OC","article-title":"Assessing patient and provider perceptions of factors associated with patient engagement in asthma care","volume":"14","author":"Sapir","year":"2017","journal-title":"Ann Am Thorac Soc"},{"key":"2026101903500485000_12.5.00135-2026.10","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02259-2019"},{"key":"2026101903500485000_12.5.00135-2026.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01633-2019"},{"key":"2026101903500485000_12.5.00135-2026.12","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202104-1040LE"},{"key":"2026101903500485000_12.5.00135-2026.13","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0587OC"},{"key":"2026101903500485000_12.5.00135-2026.14","first-page":"81","article-title":"Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma","volume":"11","author":"Haldar","year":"2017","journal-title":"Biologics"},{"key":"2026101903500485000_12.5.00135-2026.15","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-BTSabstracts.109"},{"key":"2026101903500485000_12.5.00135-2026.16","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jaip.2022.02.031","article-title":"Associations between employment and sociodemographic and health-related factors in asthmatic patients assessed at a regional severe asthma service","volume":"10","author":"Walters","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026101903500485000_12.5.00135-2026.17","unstructured":"National Institute for Health and Care Excellence . Mepolizumab for treating severe eosinophilic asthma. Date last accessed: 27 January 2026. Date last updated: 3 February 2021. www.nice.org.uk\/guidance\/ta671"},{"key":"2026101903500485000_12.5.00135-2026.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.006"},{"key":"2026101903500485000_12.5.00135-2026.19","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01836-2017"},{"key":"2026101903500485000_12.5.00135-2026.20","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01126-2017"},{"key":"2026101903500485000_12.5.00135-2026.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-003019"},{"key":"2026101903500485000_12.5.00135-2026.22","first-page":"34","article-title":"A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (F\n               eNO) in asthma management","volume":"27","author":"Arnold","year":"2018","journal-title":"Manag Care"},{"key":"2026101903500485000_12.5.00135-2026.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201806-1182OC"},{"key":"2026101903500485000_12.5.00135-2026.24","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/all.14737","article-title":"Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma","volume":"76","author":"d'Ancona","year":"2021","journal-title":"Allergy"},{"key":"2026101903500485000_12.5.00135-2026.25","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1743290"},{"key":"2026101903500485000_12.5.00135-2026.26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2018.08.005","article-title":"Disconnect of type 2 biomarkers in severe asthma; dominated by F\n               eNO as a predictor of exacerbations and periostin as predictor of reduced lung function","volume":"143","author":"Mansur","year":"2018","journal-title":"Respir Med"},{"key":"2026101903500485000_12.5.00135-2026.27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026101903500485000_12.5.00135-2026.28","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1016\/j.jaip.2022.06.050","article-title":"Corticosteroid responsiveness following mepolizumab in severe eosinophilic asthma\u2013a randomized, placebo-controlled crossover trial (MAPLE)","volume":"10","author":"Yang","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026101903500485000_12.5.00135-2026.29","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026101903500485000_12.5.00135-2026.30","doi-asserted-by":"crossref","first-page":"AB189","DOI":"10.1016\/j.jaci.2021.12.624","article-title":"The impact of baseline exhaled nitric oxide levels and blood eosinophil count on clinical outcomes in REALITI-A","volume":"149","author":"Bernstein","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"2026101903500485000_12.5.00135-2026.31","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between F\n               ENO and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2026101903500485000_12.5.00135-2026.32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.anai.2020.09.005","article-title":"Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma: a retrospective analysis","volume":"126","author":"Ramonell","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2026101903500485000_12.5.00135-2026.33","doi-asserted-by":"crossref","first-page":"4839230","DOI":"10.1155\/2018\/4839230","article-title":"Benralizumab: from the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma","volume":"2018","author":"Pelaia","year":"2018","journal-title":"Biomed Res Int"},{"key":"2026101903500485000_12.5.00135-2026.34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31324-1"},{"key":"2026101903500485000_12.5.00135-2026.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02284-5"},{"key":"2026101903500485000_12.5.00135-2026.36","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2024-BTSabstracts.334"},{"key":"2026101903500485000_12.5.00135-2026.37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975"},{"key":"2026101903500485000_12.5.00135-2026.38","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01025-2018"},{"key":"2026101903500485000_12.5.00135-2026.39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jaip.2025.10.038","article-title":"Adherence to inhaled corticosteroids and clinical outcomes following a year of tezepelumab therapy for severe asthma","volume":"14","author":"d'Ancona","year":"2026","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00135-2026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:50:47Z","timestamp":1792407047000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00135-2026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10,19]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/23120541.00135-2026"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00135-2026","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}